[Cancer immunotherapy using gammadelta T cells ex vivo expanded by bisphosphonate].
It has become clear that bisphosphonates (BPs) have diverse antitumor effects. BPs mediate their antitumor effects directly by inactivating Ras related proteins. In addition to the direct effects, BPs expand gammadelta T cells, which exhibit major histocompatibility complex-unrestricted lytic activity and inhibit osteoclastogenesis, resulting the indirect antitumor effects. Based on these pre-clinical studies, several clinical trials which focus on the antitumor effects of BPs have already started.
Kimura
Shinya
S
Kyoto University Hospital, Department of Transfusion Medicine and Cell Therapy.
D000818:Animals; D004164:Diphosphonates / Q000627:therapeutic use*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D009369:Neoplasms / Q000628:therapy*; D016692:Receptors, Antigen, T-Cell, gamma-delta; D013601:T-Lymphocytes / Q000276:immunology*
D004164:Diphosphonates; D016692:Receptors, Antigen, T-Cell, gamma-delta